For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

Most patients should not stop taking GLP-1 receptor agonists prior to elective surgery, according to updated guidance from ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...

There is also an oral GLP-1 RA peptide called MET-002, a product of Metsera’s platform for optimizing the oral delivery of ...

However, there is little evidence to show that this is the case, despite the fact that GLP-1 RA use in the year before ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

A new nationwide study led by investigators from Cedars-Sinai and other institutions reveals a significant rise in ...

These indicate that the skeletal muscle changes in GLP-1 RA treatments are a normal, adaptive process. The changes in muscle volume correspond to expectations based on age, health status and ...

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

The authors recommend that GLP-1 RA use in the perioperative period should be based on shared decision-making of the patient with procedural, anesthesia, and prescribing care teams, focusing on ...